Current Treatment for Myositis

Barsotti, Simone; Lundberg, Ingrid E.

doi:10.1007/s40674-018-0106-2

Cited by 39 publications

(26 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IIMs are histologically characterized by inflammatory cell infil tration in skeletal muscle and persisting major histocompatibility complex (MHC) class I expression in muscle fibers (4). Current treatment includes glucocorticoids combined with other immuno suppressive agent(s), but some patients are left with muscle weak ness despite this treatment (5,6). Moreover, several studies show poor correlation between the severity of muscle weakness and the degree of inflammatory cell infiltration (5,7).…”

Section: Introductionmentioning

confidence: 99%

Eccentric Resistance Training Ameliorates Muscle Weakness in a Mouse Model of Idiopathic Inflammatory Myopathies

Himori

Ashida

Tatebayashi

et al. 2021

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective. High-force eccentric contractions (ECCs) have traditionally been excluded from rehabilitation programs that include patients with idiopathic inflammatory myopathies (IIMs) due to unverified fear of causing muscle damage and inflammation. In an IIM animal model that used mice with experimental autoimmune myositis (EAM), we undertook this study to investigate whether ECC training can safely and effectively be used to counteract muscle weakness in IIM.Methods. EAM was induced in BALB/c mice by immunization with 3 injections of myosin emulsified in Freund's complete adjuvant. Controls (n = 12) and mice with EAM (n = 12) were exposed to either an acute bout of 100 ECCs or 4 weeks of ECC training (20 ECCs every other day). To induce ECCs, plantar flexor muscles were electrically stimulated while the ankle was forcibly dorsiflexed.Results. Less cell damage, as assessed by Evans blue dye uptake, was observed in the muscles of mice with EAM, compared to controls, after an acute bout of 100 ECCs (P < 0.05). Maximum Ca 2+ -activated force was decreased in skinned gastrocnemius muscle fibers from mice with EAM, and this was accompanied by increased expression of endoplasmic reticulum (ER) stress proteins, including Gsp78 and Gsp94 (P < 0.05). ECC training prevented the decrease in force and the increase in ER stress proteins and also enhanced the expression and myofibrillar binding of small heat-shock proteins (HSPs) (P < 0.05), which can stabilize myofibrillar structure and function. Conclusion.ECC training protected against the reduction in myofibrillar force-generating capacity in an IIM mouse model, and this occurred via inhibition of ER stress responses and small HSP-mediated myofibrillar stabilization.

show abstract

Section: Introductionmentioning

confidence: 99%

Eccentric Resistance Training Ameliorates Muscle Weakness in a Mouse Model of Idiopathic Inflammatory Myopathies

Himori

Ashida

Tatebayashi

et al. 2021

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…IVIg therapy may present a safe and effective treatment option, especially in patients showing no response or incomplete response to corticosteroids or who experience severe side effects on these medications. [ 17 , 18 ]…”

Section: Discussionmentioning

confidence: 99%

Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (“ProDERM Study”)

Aggarwal

Charles‐Schoeman

Scheßl³

et al. 2021

Medicine

View full text Add to dashboard Cite

Introduction: Dermatomyositis (DM) is an inflammatory myopathy characterized by distinct skin manifestations and muscle weakness. Intravenous immunoglobulin (IVIg) has been used off-label as adjuvant therapy in DM, but is not indicated for DM, due to lack of proven efficacy in a large randomized controlled trial. The objective of the ProDERM (Progress in DERMatomyositis) study was to evaluate the efficacy, safety and long-term tolerability of IVIg (Octagam 10%) in patients with DM in a randomized, placebo-controlled, double-blind, Phase III study. Methods: Adult patients with active DM who were continuing standard therapy at a stable dose were eligible for this study. Patients were randomized 1:1 to receive either 2 g/kg of IVIg or placebo, administered every 4 weeks until week 16 (First Period). Patients were switched to the alternate treatment if they showed clinical deterioration in the First Period. After response assessment at week 16, all patients on placebo and those without deterioration on IVIg entered the open-label Extension Period, receiving 2 g/kg IVIg every 4 weeks for 24 weeks. Results: The primary efficacy endpoint was the proportion of responders in the IVIg vs placebo arm at week 16, where response was defined per 2016 ACR/EULAR Myositis Response Criteria of at least minimal improvement [Total Improvement Score (TIS) ≥20] and without deterioration at 2 consecutive visits up to week 16. TIS consists of composite response criteria, combining weighted improvement in 6 core set measures (CSMs), Global Disease Activity (Physician and Patient), manual muscle testing-8 (MMT-8), Health Assessment Questionnaire, extra-muscular disease activity, and muscle enzymes. Secondary endpoints included the mean change in individual CSMs, time to improvement in TIS, time to confirmed deterioration in the First Period, and the overall proportion of patients with deteriorations. Adverse events, including infusion reactions and thromboembolic events, were recorded. Conclusions: The ProDERM study was the first to assess the long-term efficacy and safety of IVIg (Octagam 10%) in a placebo-controlled, blinded, randomized trial in DM. The study aimed to inform on the use of IVIg in the treatment of DM, and results are expected in Q3 2020. ClinicalTrials.gov Identifier: NCT02728752.

show abstract

“…One of the most widely used drugs for polymyositis is methotrexate (MTX); other therapeutic options include azathioprine, mycophenolate mofetil, cyclosporine, or biologics such as rituximab. 3 , 4 We report herein a rare case of polymyositis that responded favourably to MTX monotherapy without the use of steroids.…”

Section: Introductionmentioning

confidence: 93%

A Case Report of Favourable Response of Polymyositis to Methotrexate Monotherapy

Daoussis

Antonopoulos²,

Andonopoulos

2021

MJR

View full text Add to dashboard Cite

Current Treatment for Myositis

Cited by 39 publications

References 128 publications

Eccentric Resistance Training Ameliorates Muscle Weakness in a Mouse Model of Idiopathic Inflammatory Myopathies

Eccentric Resistance Training Ameliorates Muscle Weakness in a Mouse Model of Idiopathic Inflammatory Myopathies

Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (“ProDERM Study”)

A Case Report of Favourable Response of Polymyositis to Methotrexate Monotherapy

Contact Info

Product

Resources

About